Current Headlines

  1. Researchers Pinpoint Mechanism In Malaria Drug Resistance
    7/28/2014

    Researchers from the Washington University School of Medicine in St. Louis reported their discovery of a mechanism behind malaria parasites’ drug resistance. The discovery may also apply to other infectious diseases, such as tuberculosis and bacterial infections.

  2. CHMP Recommends Pharmacyclics’ Imbruvica For 2 Blood Cancers
    7/28/2014

    Pharmacyclics announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has given a positive opinion for its marketing authorization application for Imbruvica (ibrutinib) in the EU.

  3. Shire Partners With ArmaGen On AGT-182 For Hunter Syndrome
    7/25/2014

    Shire announced in a press release that it has partnered with ArmaGen, a U.S. biotechnology company, on AGT-182 for Hunter syndrome. The investigational enzyme replacement therapy (ERT) has potential in treating the central nervous system (CNS) symptoms of the rare disease. Shire states that the new collaboration demonstrates its commitment to the Hunter syndrome community and strengthens its rare disease pipeline.

  4. Aarhus University, Bionor Pharma Use Celgene’s Istodax To Lure HIV
    7/25/2014

    Researchers from Aarhus University and Bionor Pharma presented an abstract at the Aids 2014 congress in Melbourne regarding a small study that used Celgene’s Istodax (romidepsin) to lure HIV hidden in reservoirs in the body. Driving the virus into the open makes it susceptible to antiretroviral therapy. Medscape reports that Sharon Lewin, MD, co-chair of the meeting organizing committee, said the results were the first of its kind and significant; waking up the long-lived, sleeping forms of the virus and making it leave the cell is a big step. Steven Deeks, MD, from the University of California at San Francisco, said, "I think this is the single most important advance we've heard of at this meeting, and it's going to have a huge impact in the future."

  5. Two Australian Patients Reported HIV-Free After Cancer Treatment
    7/25/2014

    Two male Australian patients were reported to be ostensibly free from Human Immuno-deficiency Virus (HIV) following stem cell transplants to treat cancer.

  6. BCM Engineers Virus-Specific T Cells Against 5 Infections
    7/25/2014
    Scientists from the Baylor College of Medicine in Houston recently reported that they have identified a technique to rapidly generate virus-specific T cells (VSTs) against five infections that affect immunocompromised patients following bone marrow or stem cells transplantation.
  7. Meissner’s SGT (Single-Use Gauge Tee) Allows Secure Pressure Monitoring Within A Single-Use System
    7/25/2014

    Meissner’s SGT provides high accuracy pressure monitoring functionality for pre-sterilized single-use systems.

  8. Outsourced Pharma West Conference To Feature Andy Skibo Of MedImmune/AstraZeneca
    7/24/2014

    Andy Skibo, EVP Operations for MedImmune, as well as RVP Supply Biologics for AstraZeneca, will be a featured panelist at the Outsourced Pharma West Conference and Exhibition, November 10-11 in San Francisco.

  9. Celladon Licenses mSCF For Gene Therapy
    7/24/2014
    Clinical stage biotech firm Celladon Corporation announced that it has signed an exclusive, global license from Enterprise Partners Venture Capital for the membrane-bound form of the Stem Cell Factor gene (mSCF) as treatment for cardiac ischemia. The license agreement will allow Celladon to use mSCF in gene therapy applications.
  10. BioMarin And Sarah Cannon Research Institute UK Partner In EMBRACA Trial
    7/24/2014

    BioMarin Pharmaceutical and Sarah Cannon Research Institute UK (SCRI UK) announced that they have partnered to recruit patients in the ongoing Phase III EMBRACA clinical trial of BioMarin’s BMN 673 for the treatment of hereditary breast cancer with a BRCA mutation. The trial was officially initiated in October 2013 when BioMarin dosed the first BMN 673 patient.

Newsletter Signup
Newsletter Signup